Showing results (121-130 of 283) with videos related to

Sort By:
Pageof 29
Hiroshima Journal of Medical Sciences|July 11, 2018
Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor MarkersMasahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, et al.
Virology|August 28, 2010
IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clonesGoki Suda, Naoya Sakamoto, Yasuhiro Itsui, et al.
Hepatology (Baltimore, Md.)|May 4, 2011
In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosisMohsan Saeed, Masaaki Shiina, Tomoko Date, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2017
Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized MiceTakuro Uchida, Michio Imamura, C Nelson Hayes, et al.
World Journal of Gastroenterology|September 20, 2007
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinomaSoo Cheol Jeong, Hiroshi Aikata, Yoshio Katamura, et al.
Journal of Medical Virology|March 20, 2013
Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis BKeiko Arataki, C Nelson Hayes, Sakura Akamatsu, et al.
Clinical Journal of Gastroenterology|August 30, 2019
Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapyKazuki Ohya, Michio Imamura, Mitsutaka Osawa, et al.
Journal of Medical Virology|April 20, 2011
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1bYoshimasa Hashimoto, Hidenori Ochi, Hiromi Abe, et al.
Journal of Hepatology|November 30, 2010
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2bTomokazu Kawaoka, C Nelson Hayes, Waka Ohishi, et al.
Journal of Gastroenterology|October 19, 2018
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failuresMitsutaka Osawa, Michio Imamura, Yuji Teraoka, et al.
Pageof 29